Application:
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer characterized by the absence of estrogen receptors, progesterone receptors, and HER2 protein. It accounts for approximately 15-20% of breast cancer cases worldwide, with a higher incidence in younger women. TNBC is particularly challenging to treat due to its heterogeneity and the lack of targeted therapies, making chemotherapy the primary systemic treatment option. The diverse molecular subtypes of TNBC and the presence of drug-resistant cancer stem cells further complicate treatment efficacy. This complexity often leads to suboptimal treatment choices, resulting in poor prognosis, higher recurrence rates, and increased likelihood of metastasis. Consequently, patients may endure severe side effects from ineffective treatments, exacerbating their suffering and reducing their overall quality of life.
Detecting biomarkers that indicate chemotherapy’s efficiency can be a game-changer in treating TNBC patients. By utilizing advanced technologies like optical nanosensors, oncologists can monitor the real-time response of tumors to specific chemotherapy regimens. This approach allows for rapid assessment of treatment efficacy, enabling timely adjustments to therapeutic strategies.
Our innovation:
We are developing innovative near-infrared (NIR) optical nanosensors designed to report treatment efficiency in TNBC patients undergoing chemotherapy directly. This advanced technology allows for precise monitoring of a patient’s response to chemotherapy, enabling oncologists to tailor treatments more accurately. By identifying the effectiveness of chemotherapy early in the treatment process, doctors can adjust dosages or switch to alternative therapies, minimizing unnecessary exposure to ineffective drugs. This approach enhances overall health outcomes for patients and significantly reduces the debilitating side effects commonly associated with chemotherapy, ultimately improving their quality of life and reducing suffering.
Advantages:
Our technology will be the first-of-a-kind In-Situ Live Nano-reporter for chemotherapy treatment efficiency in TNBC patients.
This technology will be a valuable medical tool in improving the treatment outcome of TNBC patients and reducing valuable time and costs in unnecessary treatments.
Opportunity:
Our platform represents a potential investment opportunity for pharmaceutical companies, as it offers several advantages: It could streamline clinical trials by providing earlier indications of drug efficacy, accelerate drug development processes, and potentially lead to the creation of companion diagnostics for new TNBC therapies. With the increasing focus on personalized medicine and the high unmet need for TNBC treatment, pharmaceutical companies that invest in this technology could gain a competitive edge, potentially leading to increased market share and revenue in the oncology sector.
